Medicus Pharma Ltd., a biotech company based in the US, has received the FDA's acceptance of its Type C meeting request.
1 report, 1 independent
Updated Aug 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicus Pharma Ltd., a biotech company based in the US, has received the FDA's acceptance of its Type C meeting request.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Andrew Smith was appointed Chief Operating Officer of Medicus Pharma Ltd. on June 23, 2025.Sub-event
FDA accepted Type C meeting request from US-based biotech Medicus Pharma Ltd.1 source
Keep exploring
The entities involved
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- The FDA is currently reviewing Medtronic's submission for its MiniMed 780G system, specifically regarding its use for Type 2 diabetes and label expansion into Europe.
- Tarsus Pharmaceuticals is seeking FDA approval in the US and is listed on the Nasdaq stock exchange.
- Cloudbreak Pharma Inc. intends to meet with the FDA to review its study findings.
- FDA confirmed CMC and device plans are Phase 3 ready, coinciding with strengthening of US and EU patent estates.
Coverage
Newest first; wire copies grouped- NewsfileMedicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Secon